Long Lasting Response to the Multikinase Inhibitor Bay 43-9006 (Sorafenib) in a Heavily Pretreated Metastatic Thymic Carcinoma

被引：78

作者：

Bisagni, Giancarlo ^{[2
]}

Rossi, Giulio ^{[1
]}

Cavazza, Alberto

Sartori, Giuliana ^{[1
]}

Gardini, Giorgio

Boni, Corrado ^{[2
]}

机构：

[1] Azienda Osped Univ Policlin, Sez Anat Patol, I-41100 Modena, Italy

[2] Azienda Osped S Maria Nuova, Operat Units Oncol, Reggio Emilia, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 06期

关键词：

Thymoma; Thymic carcinoma; c-kit; CD117; Tyrosine kinase; KIT; THYMOMA;

D O I：

10.1097/JTO.0b013e3181a52e25

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Metastatic thymic carcinoma is an aggressive neoplasm for which multimodal therapies are often ineffective. We describe here a heavily pretreated patient with advanced thymic carcinoma responsive to multikinases inhibitor BAY 43-9006 (Sorafenib). Of note, a hitherto unreported c-A-it missense mutation on exon 17 (D820E) identified in tumor cells seems to explain the clinical response and highlight the key role of molecular analysis in predicting efficacy of targeted therapies even in thymic neoplasms.

引用

页码：773 / 775

页数：3

共 9 条

[1]

Dasatinib induces a response in malignant thymoma [J].

Chuah, Charles ;

Lim, Tes Hui ;

Lim, Alvin Soon Tiong ;

Tien, Sim Leng ;

Lim, Chong Hee ;

Soong, Richie ;

Linn, Yeh Ching ;

Goh, Yeow Tee ;

Cheah, Foong Koon ;

Loh, Alwin Hwai Liang .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :E56-E58

[2]

Response of thymoma to cetuximab [J].

Farina, Gabriella ;

Garassino, Marina C. ;

Gambacorta, Marcella ;

La Verde, Nicla ;

Gherardi, Giorgio ;

Scanni, Alberto .

LANCET ONCOLOGY, 2007, 8 (05) :449-450

[3]

Sorafenib inhibits the imatinib-resistant KITT6701 gatekeeper mutation in gastrointestinal stromal tumor [J].

Guo, Tianhua ;

Agaram, Narasimhan P. ;

Wong, Grace C. ;

Hom, Glory ;

D'Adamo, David ;

Maki, Robert G. ;

Schwartz, Gary K. ;

Veach, Darren ;

Clarkson, Bayard D. ;

Singer, Samuel ;

DeMatteo, Ronald P. ;

Besmer, Peter ;

Antonescu, Cristina R. .

CLINICAL CANCER RESEARCH, 2007, 13 (16) :4874-4881

[4]

Tyrosine kinase receptor expression in thymomas [J].

Henley, JD ;

Cummings, OW ;

Loehrer, PJ .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (04) :222-224

[5]

Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report [J].

Li, Xiao-feng ;

Chen, Qiang ;

Huang, Wei-xian ;

Ye, Yun-bin .

MEDICAL ONCOLOGY, 2009, 26 (02) :157-160

[6]

A review of thymic tumours [J].

Srirajaskanthan, R. ;

Toubanakis, C. ;

Dusmet, M. ;

Caplin, M. E. .

LUNG CANCER, 2008, 60 (01) :4-13

[7]

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib [J].

Strobel, P ;

Hartmann, M ;

Jakob, A ;

Mikesch, K ;

Brink, I ;

Dirnhofer, S ;

Marx, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2625-2626

[8]

Absence of gene mutations in KIT-positive thymic epithelial tumors [J].

Tsuchida, Masanori ;

Umezu, Hajime ;

Hashimoto, Takehisa ;

Shinohara, Hirohiko ;

Koike, Terumoto ;

Hosaka, Yasuko ;

Eimoto, Tadaaki ;

Hayashi, Jun-ich .

LUNG CANCER, 2008, 62 (03) :321-325

[9]

Mutational status of EGFR and KIT in thymoma and thymic carcinoma [J].

Yoh, Kiyotaka ;

Nishiwaki, Yutaka ;

Ishii, Genichiro ;

Goto, Koichi ;

Kubota, Kaoru ;

Ohmatsu, Hironobu ;

Niho, Seiji ;

Nagai, Kanji ;

Saijo, Nagahiro .

LUNG CANCER, 2008, 62 (03) :316-320

← 1 →